{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T09:17:05Z","timestamp":1782379025383,"version":"3.54.5"},"reference-count":27,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2011,11,1]],"date-time":"2011-11-01T00:00:00Z","timestamp":1320105600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,11,1]],"date-time":"2011-11-01T00:00:00Z","timestamp":1320105600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2011,11]]},"DOI":"10.1124\/dmd.111.041418","type":"journal-article","created":{"date-parts":[[2011,8,20]],"date-time":"2011-08-20T01:45:16Z","timestamp":1313804716000},"page":"2117-2129","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":53,"title":["Bovine Serum Albumin Decreases Km Values of Human UDP-Glucuronosyltransferases 1A9 and 2B7 and Increases Vmax Values of UGT1A9"],"prefix":"10.1016","volume":"39","author":[{"given":"Nenad","family":"Manevski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo Svaluto","family":"Moreolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jari","family":"Yli-Kauhaluoma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moshe","family":"Finel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.111.041418_bib1","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1046\/j.1365-2125.2002.01669.x","article-title":"In vitro-in vivo correlations for drugs eliminated by glucuronidation: investigations with the model substrate zidovudine","volume":"54","author":"Boase","year":"2002","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.111.041418_bib2","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1124\/dmd.105.005058","article-title":"Altered AZT (3\u2032-azido-3\u2032-deoxythymidine) glucuronidation kinetics in liver microsomes as an explanation for underprediction of in vivo clearance: comparison to hepatocytes and effect of incubation environment","volume":"33","author":"Engtrakul","year":"2005","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.111.041418_bib3","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/S0090-9556(24)15100-8","article-title":"In vitro glucuronidation using human liver microsomes and the pore-forming peptide alamethicin","volume":"28","author":"Fisher","year":"2000","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.111.041418_bib4","doi-asserted-by":"crossref","first-page":"251","DOI":"10.2174\/138920006776359266","article-title":"The impact of in vitro binding on in vitro-in vivo extrapolations, projections of metabolic clearance and clinical drug-drug interactions","volume":"7","author":"Grime","year":"2006","journal-title":"Curr Drug Metab"},{"key":"10.1124\/dmd.111.041418_bib5","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/S0090-9556(24)15358-5","article-title":"In vitro-in vivo scaling of CYP kinetic data not consistent with the classical Michaelis-Menten model","volume":"28","author":"Houston","year":"2000","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.111.041418_bib6","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1124\/dmd.108.023853","article-title":"Prediction of drug clearance by glucuronidation from in vitro data: use of combined cytochrome P450 and UDP-glucuronosyltransferase cofactors in alamethicin-activated human liver microsomes","volume":"37","author":"Kilford","year":"2009","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.111.041418_bib7","doi-asserted-by":"crossref","first-page":"4137","DOI":"10.1021\/bi9715627","article-title":"Evaluation of atypical cytochrome P450 kinetics with two-substrate models: evidence that multiple substrates can simultaneously bind to cytochrome P450 active sites","volume":"37","author":"Korzekwa","year":"1998","journal-title":"Biochemistry"},{"key":"10.1124\/dmd.111.041418_bib8","doi-asserted-by":"crossref","first-page":"3536","DOI":"10.1074\/jbc.M206136200","article-title":"Expression and characterization of recombinant human UDP-glucuronosyltransferases (UGTs). UGT1A9 is more resistant to detergent inhibition than other UGTs and was purified as an active dimeric enzyme","volume":"278","author":"Kurkela","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1124\/dmd.111.041418_bib9","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1097\/FPC.0b013e328011b598","article-title":"Interactions with other human UDP-glucuronosyltransferases attenuate the consequences of the Y485D mutation on the activity and substrate affinity of UGT1A6","volume":"17","author":"Kurkela","year":"2007","journal-title":"Pharmacogenet Genomics"},{"key":"10.1124\/dmd.111.041418_bib10","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/S0090-9556(24)15088-X","article-title":"The specificity of glucuronidation of entacapone and tolcapone by recombinant human UDP-glucuronosyltransferases","volume":"28","author":"Lautala","year":"2000","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.111.041418_bib11","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1023\/A:1024406221962","article-title":"Modulation of nonspecific binding in ultrafiltration protein binding studies","volume":"20","author":"Lee","year":"2003","journal-title":"Pharmacol Res"},{"key":"10.1124\/dmd.111.041418_bib12","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1021\/bc980064n","article-title":"Enzyme-assisted synthesis and structural characterization of nitrocatechol glucuronides","volume":"10","author":"Luukkanen","year":"1999","journal-title":"Bioconjug Chem"},{"key":"10.1124\/dmd.111.041418_bib13","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1124\/dmd.105.004093","article-title":"Kinetic characterization of the 1A subfamily of recombinant human UDP-glucuronosyltransferases","volume":"33","author":"Luukkanen","year":"2005","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.111.041418_bib14","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1097\/01.fpc.0000173483.13689.56","article-title":"Nomenclature update for the mammalian UDP glycosyltransferase (UGT) gene superfamily","volume":"15","author":"Mackenzie","year":"2005","journal-title":"Pharmacogenet Genomics"},{"key":"10.1124\/dmd.111.041418_bib15","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1124\/mol.110.069336","article-title":"The novel UDP glycosyltransferase 3A2: cloning, catalytic properties, and tissue distribution","volume":"79","author":"MacKenzie","year":"2011","journal-title":"Mol Pharmacol"},{"key":"10.1124\/dmd.111.041418_bib16","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0014-5793(98)01523-3","article-title":"Lipid composition of Spodoptera frugiperda (Sf9) and Trichoplusia ni (Tn) insect cells used for baculovirus infection","volume":"441","author":"Marheineke","year":"1998","journal-title":"FEBS Lett"},{"key":"10.1124\/dmd.111.041418_bib17","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1016\/j.bcp.2005.12.019","article-title":"In vitro-in vivo correlation for drugs and other compounds eliminated by glucuronidation in humans: pitfalls and promises","volume":"71","author":"Miners","year":"2006","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/dmd.111.041418_bib18","doi-asserted-by":"crossref","first-page":"196","DOI":"10.3109\/03602530903210716","article-title":"The prediction of drug-glucuronidation parameters in humans: UDP-glucuronosyltransferase enzyme-selective substrate and inhibitor probes for reaction phenotyping and in vitro-in vivo extrapolation of drug clearance and drug-drug interaction potential","volume":"42","author":"Miners","year":"2010","journal-title":"Drug Metab Rev"},{"key":"10.1124\/dmd.111.041418_bib19","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1124\/dmd.108.023598","article-title":"Determination of mRNA expression of human UDP-glucuronosyltransferases and application for localization in various human tissues by real-time reverse transcriptase-polymerase chain reaction","volume":"37","author":"Ohno","year":"2009","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.111.041418_bib20","doi-asserted-by":"crossref","first-page":"141","DOI":"10.2174\/1389200053586127","article-title":"A historical overview of the heterologous expression of mammalian UDP-glucuronosyltransferase isoforms over the past twenty years","volume":"6","author":"Radominska-Pandya","year":"2005","journal-title":"Curr Drug Metab"},{"key":"10.1124\/dmd.111.041418_bib21","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1124\/jpet.110.167916","article-title":"In vitro-in vivo extrapolation predicts drug-drug interactions arising from inhibition of codeine glucuronidation by dextropropoxyphene, fluconazole, ketoconazole, and methadone in humans","volume":"334","author":"Raungrut","year":"2010","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.111.041418_bib22","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1124\/jpet.106.118216","article-title":"Binding of inhibitory fatty acids is responsible for the enhancement of UDP-glucuronosyltransferase 2B7 activity by albumin: implications for in vitro-in vivo extrapolation","volume":"321","author":"Rowland","year":"2007","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.111.041418_bib23","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1124\/dmd.108.021105","article-title":"The \u201calbumin effect\u201d and drug glucuronidation: bovine serum albumin and fatty acid-free human serum albumin enhance the glucuronidation of UDP-glucuronosyltransferase (UGT) 1A9 substrates but not UGT1A1 and UGT1A6 activities","volume":"36","author":"Rowland","year":"2008","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.111.041418_bib24","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.jpba.2005.10.031","article-title":"Modification of the ultrafiltration technique to overcome solubility and non-specific binding challenges associated with the measurement of plasma protein binding of corticosteroids","volume":"41","author":"Taylor","year":"2006","journal-title":"J Pharm Biomed Anal"},{"key":"10.1124\/dmd.111.041418_bib25","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/j.1365-2125.2006.02588.x","article-title":"Quantitative prediction of in vivo inhibitory interactions involving glucuronidated drugs from in vitro data: the effect of fluconazole on zidovudine glucuronidation","volume":"61","author":"Uchaipichat","year":"2006","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.111.041418_bib26","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/chir.20709","article-title":"Ligand binding strategies of human serum albumin: how can the cargo be utilized?","volume":"22","author":"Varshney","year":"2010","journal-title":"Chirality"},{"key":"10.1124\/dmd.111.041418_bib27","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1124\/dmd.110.036582","article-title":"Effects of cell differentiation and assay conditions on the UDP-glucuronosyltransferase activity in Caco-2 cells","volume":"39","author":"Zhang","year":"2011","journal-title":"Drug Metab Dispos"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624225290?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624225290?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.111.041418","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T20:02:27Z","timestamp":1739908947000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955624225290"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11]]},"references-count":27,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2011,11]]}},"alternative-id":["S0090955624225290"],"URL":"https:\/\/doi.org\/10.1124\/dmd.111.041418","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2011,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bovine Serum Albumin Decreases Km Values of Human UDP-Glucuronosyltransferases 1A9 and 2B7 and Increases Vmax Values of UGT1A9","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.111.041418","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2011 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}